|
Scientific articles
The science behind CXL and PACK-CXL
|
High fluence PACK-CXL is better than low fluence PACK-CXL
Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
Landmark PACK-CXL trial published
This month, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
US Ophthalmic Review reviews CXL at the Slit Lamp
Prof. Hafezi reviews the CXL at the Slit Lamp technique in US Ophthalmic Review
Journal of Refractive Surgery publishes CXL at the Slit Lamp technique
Nikki Hafezi’s successful launch of slit lamp cross-linking technology.
Power up! More UV needed to treat IK
PACK-CXL for infectious keratitis is not like treating keratoconus with CXL.
Review on PACK-Crosslinking
The most recent and complete overview about this exciting new technology to treat corneal infections with UV light and Vitamin B2.
PACK-CXL in fungal keratitis
Article describing the successful use of PACK-CXL as primary therapy in contact lens-related fungal keratitis.
Prospective study on PACK-CXL
The so far largest study on PACK-CXL for the treatment of advanced corneal ulcers. Led by ELZA member Farhad Hafezi.
PACK-CXL can be accelerated
ELZA research shows that PACK-CXL can be accelerated from 30 minutes to 150 seconds only, while maintaining efficacy.
Defining PACK-CXL for keratitis
ELZA members define the new term for cross-linking for corneal infection.
Impact of Fluorescein on PACK-CXL
Study showing that the eye surgeon must avoid fluorescein staining of a corneal ulcer immediately prior to PACK-CXL.
CXL in Bullous Keratopathy, Veterinary Use
Scientific study on the value of PACK-CXL for the treatment of bullous keratopathy for veterinary use.